Jump to content

Labetalol: Difference between revisions

From Pharmacopedia
[unchecked revision][checked revision]
Create stub for Labetalol (linked from Category:Beta Blockers / Barbiturates / Sedative-Hypnotics Members section)
 
parser-claude: Labetalol MedTemplate refill, Top 300 stub upgrade
 
Line 1: Line 1:
{{Stub}}
{{MedTemplate
{{MedTemplate
| generic = Labetalol
| generic           = Labetalol
| classes = Beta blocker
| brand            = Trandate, Normodyne (discontinued in US)
| intro   = Labetalol is a beta blocker that also has blood-vessel-widening (vasodilating) activity through alpha blockade.
| structure        =
| classes           = [[:Category:Beta blockers|Combined alpha-1 and non-selective beta blocker]], [[:Category:Antihypertensives|Antihypertensive]]
| uses              = <vote slug="hypertension-use">Hypertension (FDA)</vote>, <vote slug="hypertensive-crisis-use">Hypertensive crisis and severe hypertension (FDA, IV)</vote>, <vote slug="pregnancy-induced-hypertension-use">Hypertension in pregnancy, including preeclampsia and eclampsia (FDA; among the safest antihypertensives in pregnancy)</vote>
| starting_dose    = Oral: 100 mg PO BID, titrate to 400 mg BID. IV: 20 mg over 2 minutes, repeat 40-80 mg every 10 minutes as needed (maximum cumulative 300 mg); continuous infusion 2 mg/minute
| preparations      = Tablets 100, 200, 300 mg; injection 5 mg/mL
| fda_max          = 2400 mg/day (oral); 300 mg total per IV bolus dosing series
| pill_id          =
| routes            = Oral, intravenous
| onset            = BP effect within hours (oral); 5-10 minutes (IV)
| duration          = 8-12 hours (oral); 4-6 hours (IV)
| halflife          = ~6-8 hours<ref name="trandate-label">FDA Prescribing Information, Trandate (labetalol hydrochloride), Prometheus/Bausch, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s022lbl.pdf</ref>
| bioavailability   = ~25% (oral; extensive first-pass)<ref name="trandate-label" />
| pregnancy        = '''Among the safest antihypertensives in pregnancy''', recommended for chronic hypertension during pregnancy and first-line for severe hypertension in preeclampsia and eclampsia<ref name="trandate-label" />
| legal            = [[USLegal:Prescription only|Rx-only]] in US
| mechanism        = <vote slug="labetalol-mech-claim">'''Combined α1-adrenergic and non-selective β-adrenergic receptor antagonist''' with approximately 1:3 α:β ratio orally and 1:7 IV. The combined α and β blockade lowers blood pressure through two complementary mechanisms: reduced cardiac output and renin secretion (the β effect, shared with all β-blockers) plus reduced peripheral vascular resistance via vasodilation (the α effect, distinguishing labetalol from selective β-blockers).</vote> The favorable pregnancy safety profile and the dual mechanism support its first-line role in pregnancy-associated hypertension and in hypertensive emergencies where rapid, controllable BP reduction is needed<ref name="trandate-label" />.
}}
}}
== References ==
<references />
[[Category:Beta blockers]]
[[Category:Antihypertensives]]

Latest revision as of 07:27, 23 May 2026

Labetalol
Trandate, Normodyne (discontinued in US)

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Common uses
Hypertension (FDA)0, Hypertensive crisis and severe hypertension (FDA, IV)0, Hypertension in pregnancy, including preeclampsia and eclampsia (FDA; among the safest antihypertensives in pregnancy)0
Pharmacy
Starting dose
Oral: 100 mg PO BID, titrate to 400 mg BID. IV: 20 mg over 2 minutes, repeat 40-80 mg every 10 minutes as needed (maximum cumulative 300 mg); continuous infusion 2 mg/minute
Preparations
Tablets 100, 200, 300 mg; injection 5 mg/mL
US FDA Max
2400 mg/day (oral); 300 mg total per IV bolus dosing series
Pharmacology
Routes
Oral, intravenous
Onset
BP effect within hours (oral); 5-10 minutes (IV)
Duration
8-12 hours (oral); 4-6 hours (IV)
Half-life
~6-8 hours[1]
Bioavailability
~25% (oral; extensive first-pass)[1]
Pregnancy
Among the safest antihypertensives in pregnancy, recommended for chronic hypertension during pregnancy and first-line for severe hypertension in preeclampsia and eclampsia[1]
Legal status
Rx-only in US
Purported mechanism
Combined α1-adrenergic and non-selective β-adrenergic receptor antagonist with approximately 1:3 α:β ratio orally and 1:7 IV. The combined α and β blockade lowers blood pressure through two complementary mechanisms: reduced cardiac output and renin secretion (the β effect, shared with all β-blockers) plus reduced peripheral vascular resistance via vasodilation (the α effect, distinguishing labetalol from selective β-blockers).0 The favorable pregnancy safety profile and the dual mechanism support its first-line role in pregnancy-associated hypertension and in hypertensive emergencies where rapid, controllable BP reduction is needed[1].

References

  1. 1.0 1.1 1.2 1.3 FDA Prescribing Information, Trandate (labetalol hydrochloride), Prometheus/Bausch, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s022lbl.pdf